Department of Internal Medicine
Endocrine-Metabolism Faculty
Medical School:
Creighton University
Residency:
Ohio State University
Fellowship:
Ohio State University
Thomas O'Dorisio, M.D.
Professor
Dr. O'Dorisio's research interests include sporadic and familial neuroendocrine tumors (e.g. carcinoid), diabetes mellitus - type 1 and type 2, and Thyroid disorders.
Honors, Awards, and Organizations
- Teaching Award (Pre-Clinical), Class of ’92; Teaching Award (Clinical and Preclinical), Class of ’83
- 1995 OMEN-TV 3 Year Award of Appreciation, The Ohio State University
- 1995 Faculty Teaching Award, from Alumni Classes
- Recipient of Donald V. Unverferth Faculty Achievement Award, Department of Internal medicine, June 1992
- Outstanding Medical Student Research Advisor (Landacre Society, April 14, 1996)
- The Best Doctors in America, Midwest Region (Woodward/White Inc.,Publisher), 1996-2002
- "Top Doctors," Columbus Monthly, August 1998
- Clinical Attending and Member, Holden Comprehensive Cancer Center, 2000-Present
- Member of the American Society of Cancer Research
Patents
- In vivo, in situ application of peptide/cell receptor kinetics utilizing radio-labelled somatostatin analogue, 204-090 and similar tyrosinated somatostatin/peptide analogues. (Principle Inventor: T.M. O’Dorisio, M.D., M. Sue O’Dorisio, M.D., Ph.D., E.. W. Martin, M.D., E.A. Woltering, M.D., joint inventors). Issued January 1997; #5,590,656.
- Multi-Tyrosinated Somatostatin Analogs. (Principle Inventor: Dr. D.H. Coy; Drs. W.A. Murphy, E.A. Woltering, M.S. O’Dorisio and T.M. O’Dorisio, joint inventors). Issued January 1997; #5,597,894.
Recent Publications
- Madsen M, Bushnell D, Menda Y, Juweid M, O’Dorisio TM, O’Dorisio MS. Potential increased tumor dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretical model. Journal of Nuclear Medicine 2006, in press.
- O’Dorisio TM, Kvols L. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a Phase II study. ASCO GI Cancers Symposium Poster Presentation, San Francisco CA, January 26-28, 2006.
- Warner RR, O’Dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview. Semin Nucl Med 2002, 32(2):79-83.